Ann Hepatobiliary Pancreat Surg.  2024 Nov;28(4):494-499. 10.14701/ahbps.23-115.

The impact of myosteatosis on postoperative outcomes and survival of patients undergoing pancreatoduodenectomy for suspected/confirmed malignancy

• Jenkins P
• MacCormick A
• Streeter A
• Puckett M
• Miles G
• Aroori S

• KMID: 2561582
• DOI: http://doi.org/10.14701/ahbps.23-115

Abstract

Backgrounds/Aims
While the effects of myosteatosis are emerging, the evidence for its use as a predictor of outcomes in patients undergoing pancreatoduodenectomy (PD) still needs to be established. The study aims to evaluate the effect of myosteatosis on the shortand long-term outcomes of PD.
Methods
We analyzed the effect of myosteatosis on the short- and long-term outcomes of patients who underwent PD between July 2006 and May 2013. Myosteatosis was measured retrospectively from preoperative computed tomography (CT) at the L3 vertebra level, and dichotomized as a binary exposure variable as < 38.5 Hounsfield unit (HU) for males, and < 36.1 HU for females.
Results
A total of 214 patient (median age 62 years, range: 41−80 years) CTs were analyzed for myosteatosis. Overall, 120/214 (56.1%) patients were classed as having myosteatosis. Both groups had similar comorbidity profiles. The presence of myosteatosis was not shown to increase the rate of any short- or long-term complication. However, pancreatic leak (29.8% vs. 13.3%; p = 0.006) and postoperative bleeding (13.8% vs. 5.0%; p = 0.034) were higher in the non-myosteatosis group. The median intensive care (2 days) and hospital stay (12 days) were the same in both groups. The 30-day mortality (myosteatosis: 3.3% vs. non-myosteatosis: 3.2%; p = 0.95), and 5-year overall survival (myosteatosis: 26.7% vs. non-myosteatosis: 31.9%; p = 0.5), were similar in both groups.
Conclusions
We have found no evidence supporting myosteatosis affecting either the short-term or long-term outcomes of patients undergoing PD for suspected/confirmed malignant tumors.

Keyword

Pancreatic neoplasms; Nutritional status

Figure

• 

  Fig. 1 Kaplan–Meier Survival curves of both the myosteatosis and non-myosteatosis group patients.

Reference

References

1. Mizrahi JD, Surana R, Valle JW, Shroff RT. 2020; Pancreatic cancer. Lancet. 395:2008–2020. DOI: 10.1016/S0140-6736(20)30974-0. PMID: 32593337.

2. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. 1982; Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 5:649–655. DOI: 10.1097/00000421-198212000-00014. PMID: 7165009.

3. Gärtner S, Krüger J, Aghdassi AA, Steveling A, Simon P, Lerch MM, et al. 2016; Nutrition in pancreatic cancer: a review. Gastrointest Tumors. 2:195–202. DOI: 10.1159/000442873. PMID: 27403414. PMCID: PMC4924449.

4. Correa-de-Araujo R, Addison O, Miljkovic I, Goodpaster BH, Bergman BC, Clark RV, et al. 2020; Myosteatosis in the context of skeletal muscle function deficit: an interdisciplinary workshop at the National Institute on Aging. Front Physiol. 11:963. DOI: 10.3389/fphys.2020.00963. PMID: 32903666. PMCID: PMC7438777.

5. Miljkovic I, Zmuda JM. 2010; Epidemiology of myosteatosis. Curr Opin Clin Nutr Metab Care. 13:260–264. DOI: 10.1097/MCO.0b013e328337d826. PMID: 20179586. PMCID: PMC2872135.

6. Shirdel M, Andersson F, Myte R, Axelsson J, Rutegård M, Blomqvist L, et al. 2020; Body composition measured by computed tomography is associated with colorectal cancer survival, also in early-stage disease. Acta Oncol. 59:799–808. DOI: 10.1080/0284186X.2020.1744716. PMID: 32228271.

7. Murnane LC, Forsyth AK, Koukounaras J, Pilgrim CH, Shaw K, Brown WA, et al. 2021; Myosteatosis predicts higher complications and reduced overall survival following radical oesophageal and gastric cancer surgery. Eur J Surg Oncol. 47:2295–2303. DOI: 10.1016/j.ejso.2021.02.008. PMID: 33640171.

8. Kim IH, Choi MH, Lee IS, Hong TH, Lee MA. 2021; Clinical significance of skeletal muscle density and sarcopenia in patients with pancreatic cancer undergoing first-line chemotherapy: a retrospective observational study. BMC Cancer. 21:77. DOI: 10.1186/s12885-020-07753-w. PMID: 33461517. PMCID: PMC7814715.

9. Aleixo GFP, Shachar SS, Nyrop KA, Muss HB, Malpica L, Williams GR. 2020; Myosteatosis and prognosis in cancer: systematic review and meta-analysis. Crit Rev Oncol Hematol. 145:102839. DOI: 10.1016/j.critrevonc.2019.102839. PMID: 31877534.

10. Rollins KE, Tewari N, Ackner A, Awwad A, Madhusudan S, Macdonald IA, et al. 2016; The impact of sarcopenia and myosteatosis on outcomes of unresectable pancreatic cancer or distal cholangiocarcinoma. Clin Nutr. 35:1103–1109. DOI: 10.1016/j.clnu.2015.08.005. PMID: 26411749.

11. Pierobon ES, Moletta L, Zampieri S, Sartori R, Brazzale AR, Zanchettin G, et al. 2021; The prognostic value of low muscle mass in pancreatic cancer patients: a systematic review and meta-analysis. J Clin Med. 10:3033. DOI: 10.3390/jcm10143033. PMID: 34300199. PMCID: PMC8306134.

12. Dusch N, Lietzmann A, Barthels F, Niedergethmann M, Rückert F, Wilhelm TJ. 2017; International Study Group of Pancreatic Surgery definitions for postpancreatectomy complications: applicability at a high-volume center. Scand J Surg. 106:216–223. DOI: 10.1177/1457496916680944. PMID: 28376656.

13. Koch M, Garden OJ, Padbury R, Rahbari NN, Adam R, Capussotti L, et al. 2011; Bile leakage after hepatobiliary and pancreatic surgery: a definition and grading of severity by the International Study Group of Liver Surgery (ISGLS). Surgery. 149:680–688. DOI: 10.1016/j.surg.2010.12.002. PMID: 21316725.

14. Simcock R, Wright J. 2020; Beyond performance status. Clin Oncol (R Coll Radiol). 32:553–561. DOI: 10.1016/j.clon.2020.06.016. PMID: 32684503. PMCID: PMC7365102.

15. Cummings P. 2011; Estimating adjusted risk ratios for matched and unmatched data: an update. Stata J. 11:290–298. DOI: 10.1177/1536867X1101100208.

16. Grambsch PM, Therneau TM. 1994; Proportional hazards tests and diagnostics based on weighted residuals. Biometrika. 81:515–526. DOI: 10.1093/biomet/81.3.515.

17. McGovern J, Dolan RD, Horgan PG, Laird BJ, McMillan DC. 2021; Computed tomography-defined low skeletal muscle index and density in cancer patients: observations from a systematic review. J Cachexia Sarcopenia Muscle. 12:1408–1417. DOI: 10.1002/jcsm.12831. PMID: 34664431. PMCID: PMC8718024.

18. Peng YC, Wu CH, Tien YW, Lu TP, Wang YH, Chen BB. 2021; Preoperative sarcopenia is associated with poor overall survival in pancreatic cancer patients following pancreaticoduodenectomy. Eur Radiol. 31:2472–2481. DOI: 10.1007/s00330-020-07294-7. PMID: 32974690.

19. West MA, van Dijk DPJ, Gleadowe F, Reeves T, Primrose JN, Abu Hilal M, et al. 2019; Myosteatosis is associated with poor physical fitness in patients undergoing hepatopancreatobiliary surgery. J Cachexia Sarcopenia Muscle. 10:860–871. DOI: 10.1002/jcsm.12433. PMID: 31115169. PMCID: PMC6711456.

20. Lee CM, Kang J. 2020; Prognostic impact of myosteatosis in patients with colorectal cancer: a systematic review and meta-analysis. J Cachexia Sarcopenia Muscle. 11:1270–1282. DOI: 10.1002/jcsm.12575. PMID: 32483936. PMCID: PMC7567135.

21. MacCormick A, Streeter A, Puckett M, Aroori S. 2023; The impact of myosteatosis on outcomes following surgery for gastrointestinal malignancy: a meta-analysis. Ann R Coll Surg Engl. 105:203–211. DOI: 10.1308/rcsann.2021.0290. PMID: 35175107. PMCID: PMC9974339.